Ocular Therapeutix
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ocular Therapeutix sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Ocular Therapeutix: 20 sponsored US clinical trials, 2 recruiting.
Ocular Therapeutix sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 10 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Neovascular Age-related Macular Degeneration, with 3 trials.
Top-decile sponsor footprint
Ocular Therapeutix ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
NCT07516132
A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy
NCT07235085
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
NCT06223958
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
NCT05814757
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
NCT05335122
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
NCT04989699
A Human Factors Study to Evaluate a Novel Intracanalicular Insertion Device in Healthy Subjects
NCT04945824
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
NCT04747977
A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
NCT04539548
Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.
NCT04362670
A Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Allergic Conjunctivitis
NCT04050865
A Study to Evaluate the Long Term Safety of OTX-TP (Sustained Release Travoprost) Intracanalicular Insert
NCT04061044
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
NCT04360174
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
NCT02914509
Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension
NCT02312544
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT02034019
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
NCT01666210
ReSure Sealant Pivotal Study
NCT01498224
I-ZIP Ocular Bandage Pivotal Study
NCT00774228
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
| Phase 3 | 10 |
What is open in the Ocular Therapeutix pipeline
2 recruiting of 20 indexed (10% open); 15 completed (75%).
Phase mix: 10 late (III/IV) vs 9 early (I/II) (balanced across stages).
Top condition: Neovascular Age-related Macular Degeneration (3 trials), 4 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ocular Therapeutix: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Ocular Therapeutix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Ocular Therapeutix page
20 registered trials is a research-attention snapshot, not an endorsement of Ocular Therapeutix or any single study.
- 2 of Ocular Therapeutix's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Neovascular Age-related Macular Degeneration is the condition Ocular Therapeutix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Neovascular Age-related Macular Degeneration trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ocular Therapeutix pipeline card: 20 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.